All‐cause mortality · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in mortality compared with heparin (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in recurrent VTE compared with heparin (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in major bleeding compared with heparin (low certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · people with ST of the leg
Fondaparinux probably leads to lower symptomatic VTE Ventilation‐perfusion scanning, helical computed… compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people with ST of the leg
Fondaparinux showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Extension of ST Ultrasonography · people with ST of the leg
Fondaparinux probably leads to lower extension of ST Ultrasonography compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence of ST Ultrasonography · people with ST of the leg
Fondaparinux probably leads to lower recurrence of ST Ultrasonography compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with ST of the leg
Fondaparinux showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Minor bleeding · people with ST of the leg
Fondaparinux showed no clear difference in minor bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of treatment · people with ST of the leg
Fondaparinux showed no clear difference in adverse effects of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Total VTE · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total VTE compared with placebo (moderate certainty).
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total DVT compared with LMWH (moderate certainty).
1 finding from 1 review
Proximal DVT · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in proximal DVT compared with LMWH (low certainty).
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in total PE compared with LMWH (moderate certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
Fondaparinux leads to higher major bleeding compared with LMWH (high certainty).
1 finding from 1 review